The effect of size, morphology and surface properties of mesoporous silica nanoparticles on pharmacokinetic aspects and potential toxicity concerns

Mesoporous silica nanoparticles (MSNs) are considered as suitable delivery vehicles considering their unique characteristics. Various physicochemical characteristics of MSNs govern their pharmacokinetic parameters which affect the disposition of these nanoparticles in the body. Along with the advantages of MSNs, the toxicity of nanoparticles entering the body is a major concern. Various factors such as particle size, surface charge, route of administration, etc., may affect organ toxicity of MSNs. The main target organs involved in the metabolism and elimination of MSNs are the kidney and the liver as well as the hematopoietic system. In this review, we first introduced the physicochemical characteristics of MSNs which affect the pharmacokinetic properties including drug absorption and bio-distribution. Thereafter, we discussed the mechanisms by which organ toxicity may occur. In this regard, the effects of various factors on organ-based MSNs toxicities and molecular mechanisms have been summarized. At last, we emphasized on the role of the physicochemical parameters on organ-based toxicities, and the proposed approaches to prevent or at least diminish MSN-related toxicities are discussed in detail.

[1]  Fei Liu,et al.  The application of mesoporous silica nanoparticles as a drug delivery vehicle in oral disease treatment , 2023, Frontiers in Cellular and Infection Microbiology.

[2]  V. Mattoli,et al.  Enhancing Methotrexate Delivery in the Brain by Mesoporous Silica Nanoparticles Functionalized with Cell-Penetrating Peptide using in Vivo and ex Vivo Monitoring. , 2023, Molecular pharmaceutics.

[3]  Dinesh Nyavanandi,et al.  A systemic review on development of mesoporous nanoparticles as a vehicle for transdermal drug delivery , 2023, Nanotheranostics.

[4]  W. Grizzle,et al.  Toxicity Assessment of Mesoporous Silica Nanoparticles upon Intravenous Injection in Mice: Implications for Drug Delivery , 2022, Pharmaceutics.

[5]  Chenying Fu,et al.  Signaling pathways and targeted therapy for myocardial infarction , 2022, Signal Transduction and Targeted Therapy.

[6]  Shiyuan Peng,et al.  Effect of Surface Functionalization and Pore Structure Type on the Release Performance of Mesoporous Silica Nanoparticles , 2022, Microporous and Mesoporous Materials.

[7]  Guangji Wang,et al.  Integrative Metabolomics, Proteomics and Transcriptomics Analysis Reveals Liver Toxicity of Mesoporous Silica Nanoparticles , 2022, Frontiers in Pharmacology.

[8]  Jie Zhou,et al.  Apigenin Attenuates Mesoporous Silica Nanoparticles-Induced Nephrotoxicity by Activating FOXO3a , 2021, Biological Trace Element Research.

[9]  Y. Sogo,et al.  Biosafety of mesoporous silica nanoparticles: a combined experimental and literature study , 2021, Journal of Materials Science: Materials in Medicine.

[10]  J. Engblom,et al.  Can mesoporous nanoparticles promote bioavailability of topical pharmaceutics? , 2021, International journal of pharmaceutics.

[11]  R. Awasthi,et al.  Albumin-Coated Mesoporous Silica Nanoparticles of Docetaxel: Preparation, Characterization, and Pharmacokinetic Evaluation. , 2021, Assay and drug development technologies.

[12]  L. McNally,et al.  Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect , 2021, Pharmaceutics.

[13]  T. Takebe,et al.  Human liver model systems in a dish , 2021, Development, growth & differentiation.

[14]  Yong Jiang Pyroptosis in liver disease. , 2020, Revista Espanola de Enfermedades Digestivas.

[15]  M. Chorilli,et al.  Exploiting mesoporous silica nanoparticles as versatile drug carriers for several routes of administration , 2020 .

[16]  S. Wuttke,et al.  Overcoming the paracetamol dose challenge with wrinkled mesoporous carbon spheres. , 2020, Journal of colloid and interface science.

[17]  R. Lin,et al.  Development and Characterization of a Glimepiride-Loaded Gelatin-Coated Mesoporous Hollow Silica Nanoparticle Formulation and Evaluation of Its Hypoglycemic Effect on Type-2 Diabetes Model Rats. , 2020, Assay and drug development technologies.

[18]  H. Lindberg,et al.  Short-term oral administration of non-porous and mesoporous silica did not induce local or systemic toxicity in mice , 2020, Nanotoxicology.

[19]  L. Walsh,et al.  Biomedical application of mesoporous silica nanoparticles as delivery systems: a biological safety perspective. , 2020, Journal of materials chemistry. B.

[20]  M. Vallet‐Regí,et al.  Mesoporous Silica Nanoparticles as Theranostic Antitumoral Nanomedicines , 2020, Pharmaceutics.

[21]  Wuli Yang,et al.  Biomimetic Mesoporous Silica Nanoparticles for Enhanced Blood Circulation and Cancer Therapy. , 2020, ACS applied bio materials.

[22]  Lixiao Zhou,et al.  TiO2 Nanoparticles Caused DNA Damage in Lung and Extra-Pulmonary Organs Through ROS-Activated FOXO3a Signaling Pathway After Intratracheal Administration in Rats , 2020, International journal of nanomedicine.

[23]  Y. Qi,et al.  STAT3, a key regulator in liver fibrosis. , 2020, Annals of hepatology.

[24]  W. Xue,et al.  Inhibition of myeloid differentiation protein 2 attenuates renal ischemia/reperfusion-induced oxidative stress and inflammation via suppressing TLR4/TRAF6/NF-kB pathway. , 2020, Life sciences.

[25]  Kyle J Isaacson,et al.  One-year chronic toxicity evaluation of single dose intravenously administered silica nanoparticles in mice and their Ex vivo human hemocompatibility. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[26]  L. Menicanti,et al.  The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome , 2020, Journal of Thrombosis and Haemostasis.

[27]  H. Khan,et al.  In-Vitro and In-Vivo Evaluation of Velpatasvir- Loaded Mesoporous Silica Scaffolds. A Prospective Carrier for Drug Bioavailability Enhancement , 2020, Pharmaceutics.

[28]  M. B. Abdul Rahman,et al.  Functionalized mesoporous silica nanoparticles templated by pyridinium ionic liquid for hydrophilic and hydrophobic drug release application , 2020 .

[29]  V. Niculescu Mesoporous Silica Nanoparticles for Bio-Applications , 2020, Frontiers in Materials.

[30]  Chuanyong Guo,et al.  Therapeutic potential of PPARγ natural agonists in liver diseases , 2020, Journal of cellular and molecular medicine.

[31]  P. Fu,et al.  Flavonoid fisetin alleviates kidney inflammation and apoptosis via inhibiting Src-mediated NF-κB p65 and MAPK signaling pathways in septic AKI mice. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[32]  Hongxia Liu,et al.  PNPLA3 I148M mediates the regulatory effect of NF‐kB on inflammation in PA‐treated HepG2 cells , 2019, Journal of cellular and molecular medicine.

[33]  D. Lin,et al.  PEGylated lipid bilayer coated mesoporous silica nanoparticles co-delivery of paclitaxel and curcumin leads to increased tumor site drug accumulation and reduced tumor burden. , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[34]  Yahya E Choonara,et al.  The Hemocompatibility of Nanoparticles: A Review of Cell–Nanoparticle Interactions and Hemostasis , 2019, Cells.

[35]  Yumei Wang,et al.  Enlarged Pore Size Chiral Mesoporous Silica Nanoparticles Loaded Poorly Water-Soluble Drug Perform Superior Delivery Effect , 2019, Molecules.

[36]  A. Farghali,et al.  Mesoporous Silica Nanoparticles Trigger Liver and Kidney Injury and Fibrosis Via Altering TLR4/NF-κB, JAK2/STAT3 and Nrf2/HO-1 Signaling in Rats , 2019, Biomolecules.

[37]  J. Batra,et al.  Encapsulation and Controlled Release of Resveratrol Within Functionalized Mesoporous Silica Nanoparticles for Prostate Cancer Therapy , 2019, Front. Bioeng. Biotechnol..

[38]  A. Mahmoud,et al.  Ferulic acid protects against methotrexate nephrotoxicity via activation of Nrf2/ARE/HO-1 signaling and PPARγ, and suppression of NF-κB/NLRP3 inflammasome axis. , 2019, Food & function.

[39]  Wenzhen Shi,et al.  GCN2 suppression attenuates cerebral ischemia in mice by reducing apoptosis and endoplasmic reticulum (ER) stress through the blockage of FoxO3a-regulated ROS production. , 2019, Biochemical and biophysical research communications.

[40]  H. Ghandehari,et al.  Subchronic toxicity of silica nanoparticles as a function of size and porosity. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[41]  Hassan A. Elgebaly,et al.  Olea europaea leaf extract up-regulates Nrf2/ARE/HO-1 signaling and attenuates cyclophosphamide-induced oxidative stress, inflammation and apoptosis in rat kidney. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[42]  S. Rajput,et al.  Investigation of in vitro permeability and in vivo pharmacokinetic behavior of bare and functionalized MCM-41 and MCM-48 mesoporous silica nanoparticles: a burst and controlled drug release system for raloxifene , 2019, Drug development and industrial pharmacy.

[43]  M. Vallet‐Regí,et al.  Mixed-charge pseudo-zwitterionic mesoporous silica nanoparticles with low-fouling and reduced cell uptake properties. , 2019, Acta biomaterialia.

[44]  Junjie Cheng,et al.  Charge-Selective Delivery of Proteins Using Mesoporous Silica Nanoparticles Fused with Lipid Bilayers. , 2019, ACS applied materials & interfaces.

[45]  Wei Zhang,et al.  Effect of Shape on Mesoporous Silica Nanoparticles for Oral Delivery of Indomethacin , 2018, Pharmaceutics.

[46]  C. Brinker,et al.  Establishing the effects of mesoporous silica nanoparticle properties on in vivo disposition using imaging-based pharmacokinetics , 2018, Nature Communications.

[47]  S. Arpicco,et al.  Strategies to Obtain Encapsulation and Controlled Release of Pentamidine in Mesoporous Silica Nanoparticles , 2018, Pharmaceutics.

[48]  A. Allam,et al.  Commiphora molmol protects against methotrexate-induced nephrotoxicity by up-regulating Nrf2/ARE/HO-1 signaling. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[49]  D. Klionsky,et al.  Necrotic, apoptotic and autophagic cell fates triggered by nanoparticles , 2018, Autophagy.

[50]  Cheng Xu,et al.  Mesoporous silica nanorods for improved oral drug absorption , 2018, Artificial cells, nanomedicine, and biotechnology.

[51]  J. Devoisselle,et al.  Biosafety of Mesoporous Silica Nanoparticles , 2018, Biomimetics.

[52]  Lei Shang,et al.  Superiority of amino-modified chiral mesoporous silica nanoparticles in delivering indometacin , 2018, Artificial cells, nanomedicine, and biotechnology.

[53]  Wei Chen,et al.  Mesoporous silica nanoparticles induced hepatotoxicity via NLRP3 inflammasome activation and caspase-1-dependent pyroptosis. , 2018, Nanoscale.

[54]  M. Vallet‐Regí,et al.  Mesoporous silica nanoparticles in nanomedicine applications , 2018, Journal of Materials Science: Materials in Medicine.

[55]  S. Rajput,et al.  Etoposide encapsulated functionalized mesoporous silica nanoparticles: Synthesis, characterization and effect of functionalization on dissolution kinetics in simulated and biorelevant media , 2018 .

[56]  N. Khashab,et al.  Mesoporous Silica and Organosilica Nanoparticles: Physical Chemistry, Biosafety, Delivery Strategies, and Biomedical Applications , 2018, Advanced healthcare materials.

[57]  S. Laurent,et al.  Toxicity of TiO2 nanoparticles on the NRK52E renal cell line , 2017, Molecular & Cellular Toxicology.

[58]  Bruno A. Cisterna,et al.  Nanotechnology and primary hemostasis: Differential effects of nanoparticles on platelet responses. , 2017, Vascular pharmacology.

[59]  F. Wilkinson,et al.  The Role of Nrf2 in Cardiovascular Function and Disease , 2017, Oxidative medicine and cellular longevity.

[60]  N. Fan,et al.  Multimodal nanoporous silica nanoparticles functionalized with aminopropyl groups for improving loading and controlled release of doxorubicin hydrochloride. , 2017, Materials science & engineering. C, Materials for biological applications.

[61]  Junchao Duan,et al.  Silica nanoparticles induce liver fibrosis via TGF-β1/Smad3 pathway in ICR mice , 2017, International journal of nanomedicine.

[62]  Tian Xia,et al.  Facilitating Translational Nanomedicine via Predictive Safety Assessment. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[63]  L. Aleksunes,et al.  Xenobiotic transporters and kidney injury. , 2017, Advanced drug delivery reviews.

[64]  Y. Hung,et al.  Molecular Elucidation of Biological Response to Mesoporous Silica Nanoparticles in Vitro and in Vivo. , 2017, ACS applied materials & interfaces.

[65]  Qinfu Zhao,et al.  A comparison between sphere and rod nanoparticles regarding their in vivo biological behavior and pharmacokinetics , 2017, Scientific Reports.

[66]  H. Naegeli,et al.  MyD88-dependent pro-interleukin-1β induction in dendritic cells exposed to food-grade synthetic amorphous silica , 2017, Particle and Fibre Toxicology.

[67]  L. Godderis,et al.  Toxicology of silica nanoparticles: an update , 2017, Archives of Toxicology.

[68]  D. Oupický,et al.  Surface PEGylation of Mesoporous Silica Nanorods (MSNR): Effect on loading, release, and delivery of mitoxantrone in hypoxic cancer cells , 2017, Scientific Reports.

[69]  D. Oupický,et al.  Surface PEGylation of Mesoporous Silica Nanorods (MSNR): Effect on loading, release, and delivery of mitoxantrone in hypoxic cancer cells , 2017, Scientific Reports.

[70]  Y. Hu,et al.  Inhibition of Kupffer Cell Autophagy Abrogates Nanoparticle‐Induced Liver Injury , 2017, Advanced healthcare materials.

[71]  O. Farokhzad,et al.  Nanomedicines for renal disease: current status and future applications , 2016, Nature Reviews Nephrology.

[72]  Chengzhong Yu,et al.  Amine functionalized cubic mesoporous silica nanoparticles as an oral delivery system for curcumin bioavailability enhancement , 2016, Nanotechnology.

[73]  Jing Guan,et al.  Blood clot initiation by mesoporous silica nanoparticles: dependence on pore size or particle size? , 2016, Journal of materials chemistry. B.

[74]  W. Dai,et al.  Amphipathic silica nanoparticles induce cytotoxicity through oxidative stress mediated and p53 dependent apoptosis pathway in human liver cell line HL-7702 and rat liver cell line BRL-3A. , 2016, Colloids and surfaces. B, Biointerfaces.

[75]  B. Yan,et al.  Vitexin attenuates acute doxorubicin cardiotoxicity in rats via the suppression of oxidative stress, inflammation and apoptosis and the activation of FOXO3a. , 2016, Experimental and therapeutic medicine.

[76]  R. C.-Gaudreault,et al.  Size-Controlled Functionalized Mesoporous Silica Nanoparticles for Tunable Drug Release and Enhanced Anti-Tumoral Activity , 2016 .

[77]  Nan Zheng,et al.  Contribution of carboxyl modified chiral mesoporous silica nanoparticles in delivering doxorubicin hydrochloride in vitro: pH-response controlled release, enhanced drug cellular uptake and cytotoxicity. , 2016, Colloids and surfaces. B, Biointerfaces.

[78]  Lu Xiao,et al.  Zinc oxide nanoparticles induce renal toxicity through reactive oxygen species. , 2016, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[79]  Abderrahim Nemmar,et al.  Oxidative stress, inflammation, and DNA damage in multiple organs of mice acutely exposed to amorphous silica nanoparticles , 2016, International journal of nanomedicine.

[80]  Mohd Ali Hashim,et al.  Superoxide Ion: Generation and Chemical Implications. , 2016, Chemical reviews.

[81]  Jie Zhou,et al.  Autophagy upregulation promotes macrophages to escape mesoporous silica nanoparticle (MSN)-induced NF-κB-dependent inflammation , 2016, Inflammation Research.

[82]  Hongzhuo Liu,et al.  Comparison of bare and amino modified mesoporous silica@poly(ethyleneimine)s xerogel as indomethacin carrier: Superiority of amino modification. , 2016, Materials science & engineering. C, Materials for biological applications.

[83]  Linlin Li,et al.  Biodistribution, excretion, and toxicity of mesoporous silica nanoparticles after oral administration depend on their shape. , 2015, Nanomedicine : nanotechnology, biology, and medicine.

[84]  M. Mahboob,et al.  Biomarkers of oxidative stress for in vivo assessment of toxicological effects of iron oxide nanoparticles , 2015, Saudi journal of biological sciences.

[85]  Luis Augusto Visani de Luna,et al.  Monitoring the Hemolytic Effect of Mesoporous Silica Nanoparticles after Human Blood Protein Corona Formation , 2015 .

[86]  Jiandong Wang,et al.  Genotoxicity of mesoporous silica nanoparticles in human embryonic kidney 293 cells. , 2015, Drug testing and analysis.

[87]  Amalie Thit,et al.  Toxic mechanisms of copper oxide nanoparticles in epithelial kidney cells. , 2015, Toxicology in vitro : an international journal published in association with BIBRA.

[88]  Ling Zhao,et al.  Inflammatory responses and inflammation-associated diseases in organs , 2015, Oncotarget.

[89]  Toshiro Hirai,et al.  Protein corona changes mediated by surface modification of amorphous silica nanoparticles suppress acute toxicity and activation of intrinsic coagulation cascade in mice , 2015, Nanotechnology.

[90]  W. Goessler,et al.  Cellular uptake and toxicity effects of silver nanoparticles in mammalian kidney cells , 2015, Journal of applied toxicology : JAT.

[91]  Stefan Tenzer,et al.  Protein corona of nanoparticles: distinct proteins regulate the cellular uptake. , 2015, Biomacromolecules.

[92]  X. Chen,et al.  Renal interstitial fibrosis induced by high-dose mesoporous silica nanoparticles via the NF-κB signaling pathway , 2014, International journal of nanomedicine.

[93]  Y. Yoshioka,et al.  Evaluation of silica nanoparticle binding to major human blood proteins , 2014, Nanoscale Research Letters.

[94]  V. Rotello,et al.  Effect of nano-scale curvature on the intrinsic blood coagulation system. , 2014, Nanoscale.

[95]  Chengzhong Yu,et al.  Effect of surface functionality of silica nanoparticles on cellular uptake and cytotoxicity. , 2014, Molecular pharmaceutics.

[96]  R. Nho,et al.  FoxO3a and disease progression. , 2014, World journal of biological chemistry.

[97]  M. Moeller,et al.  Mechanisms of epithelial repair and regeneration after acute kidney injury. , 2014, Seminars in nephrology.

[98]  Tingting Ding,et al.  SiO2 nanoparticle-induced impairment of mitochondrial energy metabolism in hepatocytes directly and through a Kupffer cell-mediated pathway in vitro , 2014, International journal of nanomedicine.

[99]  F. Alessandrini,et al.  Surface modifications of silica nanoparticles are crucial for their inert versus proinflammatory and immunomodulatory properties , 2014, International journal of nanomedicine.

[100]  Jin Sun,et al.  The investigation of MCM-48-type and MCM-41-type mesoporous silica as oral solid dispersion carriers for water insoluble cilostazol , 2014, Drug development and industrial pharmacy.

[101]  G. Mainelis,et al.  Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention , 2014, Cancer biology & medicine.

[102]  Xiue Jiang,et al.  Impact of shape and pore size of mesoporous silica nanoparticles on serum protein adsorption and RBCs hemolysis. , 2014, ACS applied materials & interfaces.

[103]  Alokita Karmakar,et al.  Neurotoxicity of nanoscale materials , 2014, Journal of food and drug analysis.

[104]  B. Trewyn,et al.  Mimicking red blood cell lipid membrane to enhance the hemocompatibility of large-pore mesoporous silica. , 2014, ACS applied materials & interfaces.

[105]  Xiao-ling Fang,et al.  In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[106]  Y. Yoshioka,et al.  Acute and chronic nephrotoxicity of platinum nanoparticles in mice , 2013, Nanoscale Research Letters.

[107]  M. Avci-Adali,et al.  Hemocompatibility evaluation of different silver nanoparticle concentrations employing a modified Chandler-loop in vitro assay on human blood. , 2013, Acta biomaterialia.

[108]  J. Xu,et al.  Nanosized copper oxide induces apoptosis through oxidative stress in podocytes , 2013, Archives of Toxicology.

[109]  M. Bayindir,et al.  Impact of mesoporous silica nanoparticle surface functionality on hemolytic activity, thrombogenicity and non-specific protein adsorption. , 2013, Journal of materials chemistry. B.

[110]  Linlin Li,et al.  The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. , 2013, Biomaterials.

[111]  Eric C. Carnes,et al.  Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. , 2013, Accounts of chemical research.

[112]  B. Trewyn,et al.  Interaction effects of mesoporous silica nanoparticles with different morphologies on human red blood cells , 2013 .

[113]  Y. Liu,et al.  Cardiovascular Toxicity of Different Sizes Amorphous Silica Nanoparticles in Rats After Intratracheal Instillation , 2013, Cardiovascular Toxicology.

[114]  Mi‐Sun Kim,et al.  The comparative immunotoxicity of mesoporous silica nanoparticles and colloidal silica nanoparticles in mice , 2013, International journal of nanomedicine.

[115]  J. Xu,et al.  Nano copper induced apoptosis in podocytes via increasing oxidative stress. , 2012, Journal of Hazardous Materials.

[116]  Xinglu Huang,et al.  The shape effect of PEGylated mesoporous silica nanoparticles on cellular uptake pathway in Hela cells , 2012 .

[117]  M. Morille,et al.  Implication of oxidative stress in size-dependent toxicity of silica nanoparticles in kidney cells. , 2012, Toxicology.

[118]  Jürgen Lademann,et al.  Skin penetration and cellular uptake of amorphous silica nanoparticles with variable size, surface functionalization, and colloidal stability. , 2012, ACS nano.

[119]  M. Odén,et al.  Shape engineering vs organic modification of inorganic nanoparticles as a tool for enhancing cellular internalization , 2012, Nanoscale Research Letters.

[120]  Y. Liu,et al.  Mesoporous silica nanoparticles with manipulated microstructures for drug delivery. , 2012, Colloids and surfaces. B, Biointerfaces.

[121]  H. Gu,et al.  Molecular confinement in fluorescent magnetic mesoporous silica nanoparticles: effect of pore size on multifunctionality. , 2012, Chemphyschem : a European journal of chemical physics and physical chemistry.

[122]  D. Basile,et al.  Pathophysiology of acute kidney injury. , 2012, Comprehensive Physiology.

[123]  Linlin Li,et al.  Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery , 2012, Advanced materials.

[124]  Zongxi Li,et al.  Mesoporous silica nanoparticles in biomedical applications. , 2012, Chemical Society reviews.

[125]  Dong Chen,et al.  Pathological mechanisms of liver injury caused by continuous intraperitoneal injection of silica nanoparticles. , 2012, Biomaterials.

[126]  Michiel Sprik,et al.  The Silica-Water Interface: How the Silanols Determine the Surface Acidity and Modulate the Water Properties. , 2012, Journal of chemical theory and computation.

[127]  F. Wagener,et al.  Heme Oxygenase, Inflammation, and Fibrosis: The Good, the Bad, and the Ugly? , 2012, Front. Pharmacol..

[128]  S. Słomkowski,et al.  Effect of surface modification of silica nanoparticles on toxicity and cellular uptake by human peripheral blood lymphocytes in vitro , 2012, Nanotoxicology.

[129]  Zhiwei Sun,et al.  Cytotoxicity and mitochondrial damage caused by silica nanoparticles. , 2011, Toxicology in vitro : an international journal published in association with BIBRA.

[130]  Stefan Tenzer,et al.  Nanoparticle size is a critical physicochemical determinant of the human blood plasma corona: a comprehensive quantitative proteomic analysis. , 2011, ACS nano.

[131]  Taeghwan Hyeon,et al.  Multifunctional mesoporous silica nanocomposite nanoparticles for theranostic applications. , 2011, Accounts of chemical research.

[132]  I. Rahman,et al.  FOXO3 Deficiency Leads to Increased Susceptibility to Cigarette Smoke-Induced Inflammation, Airspace Enlargement, and Chronic Obstructive Pulmonary Disease , 2011, The Journal of Immunology.

[133]  Dong Chen,et al.  The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. , 2011, ACS nano.

[134]  Hamidreza Ghandehari,et al.  Impact of silica nanoparticle design on cellular toxicity and hemolytic activity. , 2011, ACS nano.

[135]  R. Tan,et al.  Physical state and dissolution of ibuprofen formulated by co-spray drying with mesoporous silica: effect of pore and particle size. , 2011, International journal of pharmaceutics.

[136]  Tian Xia,et al.  Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. , 2011, ACS nano.

[137]  Victor S-Y Lin,et al.  Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects. , 2011, ACS nano.

[138]  Y. Yoshioka,et al.  Effect of surface properties of silica nanoparticles on their cytotoxicity and cellular distribution in murine macrophages , 2011, Nanoscale research letters.

[139]  Yaping Li,et al.  In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. , 2011, Small.

[140]  Patrick Augustijns,et al.  Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[141]  Donna D. Zhang,et al.  Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. , 2010, Antioxidants & redox signaling.

[142]  C. Mou,et al.  Intracellular pH-responsive mesoporous silica nanoparticles for the controlled release of anticancer chemotherapeutics. , 2010, Angewandte Chemie.

[143]  Juan L. Vivero-Escoto,et al.  Mesoporous silica nanoparticles: structural design and applications , 2010 .

[144]  Christy L Haynes,et al.  Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity. , 2010, Journal of the American Chemical Society.

[145]  N. Jacobsen,et al.  Role of oxidative damage in toxicity of particulates , 2010, Free radical research.

[146]  Feng Gao,et al.  Oxidative stress contributes to silica nanoparticle-induced cytotoxicity in human embryonic kidney cells. , 2009, Toxicology in vitro : an international journal published in association with BIBRA.

[147]  María Vallet-Regí,et al.  Influence of mesoporous structure type on the controlled delivery of drugs: release of ibuprofen from MCM-48, SBA-15 and functionalized SBA-15 , 2009 .

[148]  J. Pounds,et al.  Macrophage responses to silica nanoparticles are highly conserved across particle sizes. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[149]  T. Bein,et al.  Tuning drug uptake and release rates through different morphologies and pore diameters of confined mesoporous silica , 2009 .

[150]  Patrick Brochard,et al.  In vitro effects of nanoparticles on renal cells , 2008, Particle and Fibre Toxicology.

[151]  C. Hoppel,et al.  Ischemic defects in the electron transport chain increase the production of reactive oxygen species from isolated rat heart mitochondria. , 2008, American journal of physiology. Cell physiology.

[152]  Chung-Yuan Mou,et al.  The effect of surface charge on the uptake and biological function of mesoporous silica nanoparticles in 3T3-L1 cells and human mesenchymal stem cells. , 2007, Biomaterials.

[153]  Patrick Augustijns,et al.  Enhanced release of itraconazole from ordered mesoporous SBA-15 silica materials. , 2007, Chemical communications.

[154]  G. Stucky,et al.  Oxide hemostatic activity. , 2006, Journal of the American Chemical Society.

[155]  Shilun Qiu,et al.  Controlled release of Captopril by regulating the pore size and morphology of ordered mesoporous silica , 2006 .

[156]  Takafumi Yoshida,et al.  Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 production , 2006, Oncogene.

[157]  Christopher J. Parsons,et al.  Mechanisms of liver fibrosis. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[158]  B. Rehermann,et al.  The liver as an immunological organ , 2006, Hepatology.

[159]  G. Wolf,et al.  From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. , 2005, Diabetes.

[160]  B. Rehermann,et al.  The liver as an immunological organ , 2004 .

[161]  Bice Fubini,et al.  Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. , 2003, Free radical biology & medicine.

[162]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[163]  R. Gaynor,et al.  Role of the NF-kappaB pathway in the pathogenesis of human disease states. , 2001, Current molecular medicine.

[164]  K. Itoh,et al.  An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. , 1997, Biochemical and biophysical research communications.

[165]  B. Morrow,et al.  Surface vibrational modes of silanol groups on silica , 1992 .

[166]  Valerie C. Scanlon,et al.  Essentials of Anatomy and Physiology , 1991 .

[167]  A. Saboury,et al.  Mesoporous silica nanoparticles for therapeutic/diagnostic applications. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[168]  A. Farghali,et al.  Cardiac and pulmonary toxicity of mesoporous silica nanoparticles is associated with excessive ROS production and redox imbalance in Wistar rats. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[169]  Qiang Zhang,et al.  Overcoming multiple gastrointestinal barriers by bilayer modified hollow mesoporous silica nanocarriers. , 2018, Acta biomaterialia.

[170]  M. Lindén Biodistribution and Excretion of Intravenously Injected Mesoporous Silica Nanoparticles: Implications for Drug Delivery Efficiency and Safety. , 2018, The Enzymes.

[171]  Yubin Li,et al.  The Role of Autophagy in Nanoparticles-Induced Toxicity and Its Related Cellular and Molecular Mechanisms. , 2018, Advances in experimental medicine and biology.

[172]  Mohanan P V,et al.  Cellular interactions of zinc oxide nanoparticles with human embryonic kidney (HEK 293) cells. , 2017, Colloids and surfaces. B, Biointerfaces.

[173]  Q. Qian Inflammation: A Key Contributor to the Genesis and Progression of Chronic Kidney Disease. , 2017, Contributions to nephrology.

[174]  S. Sapino,et al.  Mesoporous silica as topical nanocarriers for quercetin: characterization and in vitro studies. , 2015, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[175]  P. Sil,et al.  Nanotoxicity: oxidative stress mediated toxicity of metal and metal oxide nanoparticles. , 2014, Journal of nanoscience and nanotechnology.

[176]  H. Schlitt,et al.  [The liver as an immunological organ]. , 2011, Zeitschrift fur Gastroenterologie.

[177]  Marie Carrière,et al.  Toxicological consequences of TiO2, SiC nanoparticles and multi-walled carbon nanotubes exposure in several mammalian cell types: an in vitro study , 2010 .

[178]  Juan L. Vivero-Escoto,et al.  Mesoporous silica nanoparticles for reducing hemolytic activity towards mammalian red blood cells. , 2009, Small.